Skip to content

Acustocerebrography (ACG) in Severe Brain Injury

Study on Additive Use of Non-invasive Acustocerebrography in Patients Suspect to Severe Brain Injury

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03635736
Acronym
ACG-BrainICU
Enrollment
30
Registered
2018-08-17
Start date
2018-08-14
Completion date
2021-10-31
Last updated
2020-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Acute

Keywords

brain damage, sonography

Brief summary

The study will enable the clinical applicability of the multiple-spectral-sonography for detection of severe brain injury in ICU patients. For this, the ACG diagnostic system (Sonovum AG, Leipzig, Germany) should be used as additional diagnostic tool in prospective single-center study.

Detailed description

A multiple-step procedure, including repetition of the clinical examinations after a waiting period and use of additional technical diagnostic tools e.g. magnetic resonance tomography and Transcranial Doppler sonography (TCD) are needed for determining of severe brain injury and irreversible brain function failure. This study will enable the clinical applicability of the multiple-spectral-sonography for detection of severe brain injury in ICU patients. For this, the ACG diagnostic system (Sonovum AG, Leipzig, Germany) should be used as additional diagnostic tool in prospective single-center study. The ACG-method is a bedside non-invasive sonography that has been shown to be useful in previous studies analyzing circulatory changes in rat cerebral blood vessels, for example, to distinguish between brain-ischemia and -hemorrhage. Additionally, in the case of brain death, the spontaneous electrical activity, which can be measured by means of ACG as global elasticity, was not longer detectable. In the study should include 30 adult ICU-patients in patients suspect to severe brain injury. The inclusion of patients will be started if written informed consent was obtained from participants or their representatives. After the inclusion, the ACG is measured three times a day. In addition, the routinely practice (treatment and diagnostic) for patients with severe brain injury (neurological clinical examinations, use of additional technical diagnostic tools e.g. magnetic resonance tomography and Transcranial Doppler sonography (TCD); Standard Medical Care) should be made and documented. From all patients basic demographic data, pre-morbidity, vital parameters, blood parameters, Illness severity scores (APACHE-II, SOFA, GCS), drug levels, microbiological results and cranial MRI/CT results will be recorded.

Interventions

OTHERmultiple-spectral-sonography as acustocerebrography (ACG)

After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.

Sponsors

University of Rostock
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* suspected severe brain injury

Exclusion criteria

* open skull brain trauma * skull fractures in the temporal area * decompression-craniotomy

Design outcomes

Primary

MeasureTime frameDescription
acustocerebrography (ACG)after inclusion: time-point 0 hourschanges in the ACG during the course of disease (especially the dimensionality of the time to flight of the ultrasound signal)

Secondary

MeasureTime frameDescription
SOFAevery day, at least after 28 daysEvaluation of the SOFA-Score
acustocerebrography (ACG)Every day to 3 time-points. The measurements will be stopped after final evaluation of the neurological status, at least after 28 dayschanges in the ACG during the course of disease (especially the dimensionality of the time to flight of the ultrasound signal)

Countries

Germany

Contacts

Primary ContactMartin Sauer, MD
martin.sauer@uni-rostock.de+493814946409
Backup ContactGeorg Richter
georg.richter@med.uni-rostock.de+493814946409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026